City Therapeutics Secures $99.5 Million in Latest Series B Funding Round

City Therapeutics secured $99.5 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

City Therapeutics Raises $99.5 million in Funding

City Therapeutics is a Million Series A Financing to Lead the Future of RNAi-based Digital Health company focused on Advance Next-Generation RNAi Therapeutics.

Investors Behind the Funding

The round was backed by undisclosed investors. Funding Intelligence tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

City Therapeutics operates in Healthcare & Life Sciences. City Therapeutics's Series B round shows investors are still backing digital health platforms with real scale narratives. At $100M, the deal suggests buyers want category leaders that can turn AI, automation, or workflow leverage into durable enterprise demand.

Strategic Use of Funds

Advance Next-Generation RNAi Therapeutics

Looking Ahead

City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics

Source reference: original announcement/article.